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Background: SMAD4 is a gastrointestinal malignancy-specific tumor suppressor gene found mutated in one third
of colorectal cancer specimens and half of pancreatic tumors. SMAD4 inactivation by allelic deletion or intragenic
mutation mainly occurs in the late stage of human pancreatic ductal adenocarcinoma (PDAC). Various studies have
proposed potential SMAD4-mediated anti-tumor effects in human malignancy; however, the relevance of SMAD4 in
the PDAC molecular phenotype has not yet been fully characterized.
Methods: The AsPC-1, CFPAC-1 and PANC-1 human PDAC cell lines were used. The restoration or knockdown of
SMAD4 expression in PDAC cells were confirmed by western blotting, luciferase reporter and immunofluorescence
assays. In vitro cell proliferation, xenograft, wound healing, quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR), Western blotting, and immunohistochemistry analysis were conducted using PDAC cells in
which SMAD4 was either overexpressed or knocked down.
Results: Here, we report that re-expression of SMAD4 in SMAD4-null PDAC cells does not affect tumor cell growth
in vitro or in vivo, but significantly enhances cells migration in vitro. SMAD4 restoration transcriptionally activates the
TGF-β1/Nestin pathway and induces expression of several transcriptional factors. In contrast, SMAD4 loss in PDAC
leads to increased expression of E-cadherin, vascular endothelial growth factor (VEGF), epidermal growth factor
receptor (EGFR) and CD133. Furthermore, SMAD4 loss causes alterations to multiple kinase pathways (particularly
the phosphorylated ERK/p38/Akt pathways), and increases chemoresistance in vitro. Finally, PDAC cells with intact
SMAD4 are more sensitive to TGF-β1 inhibitor treatment to reduced cell migration; PDAC cells lacking SMAD4
showed decreased cell motility in response to EGFR inhibitor treatment.
Conclusions: This study revealed the molecular basis for SMAD4-dependent differences in PDAC with the aim of
identifying the subset of patients likely to respond to therapies targeting the TGF-β or EGFR signaling pathways and
of identifying potential therapeutic interventions for PDAC patients with SMAD4 defects.
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Pancreatic cancer is one of the most insidious forms of
human cancer whose incidence nearly equals its death
rate. Histologically, ductal adenocarcinomas of the pan-
creas (PDAC) account for > 90% of all exocrine pancreatic
cancers. PDAC remains the eighth leading cause of cancer
death worldwide, with the lowest 5-year survival rate of
any gastrointestinal cancer. Several features conspire to* Correspondence: khcheng@faculty.nsysu.edu.tw
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unless otherwise stated.make PDAC a formidable clinical issue: poor early detec-
tion, the advanced nature of most tumors at the time of
diagnosis, and lack of specific or effective therapy. In con-
trast to other major cancers, decades of clinical trials have
failed to provide appreciable survival and less toxicity
benefit for PDAC [1]. For example, FOLFIRINOX and
nab-Paclitaxel for treatment of advanced pancreatic
cancer have shown to be effective for overall survival,
progression-free survival, and response rate, but was as-
sociated with increased toxicity and serious side effects
[2-4]. Indeed, this continual cycle of clinical trial for PDAC
therapy followed by failure has led some to conclude thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lying this particular type of lethal disease [5,6].
A number of studies of PDAC have elucidated a de-
tailed profile of genetic alterations associated with PDAC
initiation and progression — including the activation
KRAS and loss of INK4A, p53, and SMAD4 — providing
clues for investigation of the molecular and biochemical
basis for this malignancy [7,8]. SMAD4 is recognized as
an intracellular common mediator for the TGF-β super-
family signaling pathways, including TGF-β1, activin, and
BMP signaling, responsible for embryonic patterning,
differentiation and a variety of homeostatic processes
[9,10]. During the initiation phase of carcinogenesis, most
malignant epithelial tumors develop resistance to TGF-β/
SMAD-mediated growth inhibition. However, excessive
levels of TGF-β1 are associated with malignant tumor
progression in many cancers, suggesting that inactivation
of the SMAD proteins could be an important event in this
process [11]. With respect to cellular growth control, the
effects of TGF-β are highly dependent on the cell type and
cell context, which exert alternating growth-promoting
and growth-inhibitory effects in different cell types and at
different stages of tumorigenesis. Several independent
studies indicate that deletions or intragenic mutations of
the SMAD4 gene are present in more than 50% of human
PDACs, but are rare in other malignancies such as lung or
breast cancer [12-16]. Hence, SMAD4 is a distinguishing
molecular feature of two major types of PDAC. Although
many lines of evidence indicate that SMAD4 status in
PDAC is associated with specific histopathological
phenotypes, the detailed molecular basis of SMAD4-
dependent phenotypic changes in cancer biology has yet
to be determined.
Although many lines of evidence indicate that inacti-
vation of SMAD4 in PDAC is generally restricted to
high grade Pancreatic intraepithelial neoplasia (PanIN)
and PDAC, implying a specific role for SMAD4 in ma-
lignant progression, the specific anti-tumorigenic im-
pact of SMAD4 loss has not been fully characterized
[8,17]. Notably, studies of human cell lines have given
inconsistent results of how SMAD4 status influences
TGF-β responsiveness and of other tumor biological
properties, leading to conflicting conclusions on the im-
pact of SMAD4 defects on PDAC prognosis [18,19].
Overall, these studies suggest that TGF-β/SMAD4 sig-
naling may have pleiotropic and context-dependent
roles during PDAC progression. These features add sig-
nificant complexity to attempts to design therapeutic
strategies to deregulate the SMAD4 pathway. In this
study, we used SMAD4-proficient and -deficient human
PDAC cell lines AsPC-1, CFPAC-1, and PANC-1 to
compare the molecular profiles of SMAD4-positive and
-negative PDAC cells; assess their relationship to SMAD4
status; and further demonstrate the ability of SMAD4 tomodulate cell proliferation, affect cell motility, regulate
the epithelial-mesenchymal-transition (EMT) process,
activate kinase pathways, change expression of cancer
stem-like cell (CSC) markers and affect sensitivity to
chemodrugs in PDAC. The objective of the present
study was therefore to dissect the molecular circuits
that contribute to the inactivation of SMAD4 in differ-
ent phenotypes of PDAC.
Methods
Cell culture, RNA isolation, and cDNA synthesis and
inhibitors treatments
The HEK293T and human PDAC cell lines were obtained
from sources described previously [8,20]. Treatments
with TGF-β1 (5 ng/ml), cisplatin, paciltaxol, gemcita-
bine, SB231542 and gefitinib were performed according
to previously-described procedures [20,21]. The RNA
isolation and cDNA synthesis from the cell lines were
also conducted according to previously-described proto-
cols [20,22].
Plasmid and retroviral construction
A full length cDNA clone for the SMAD4 gene was ori-
ginally obtained from the Bert Vogelstein laboratory and
subcloned in pBabe-puro plasmid (Addgene, Cambridge,
MA) to create a pBabe-SMAD4-puro vector [21]. In
brief, for SMAD4 gene restoration, pBabe-puro plasmid
was digested with restriction enzyme BamHI and Hind
ΙΙΙ to obtain the full length of SMAD4 cDNA, then li-
gated into BamHI/XhoI-digested pBabe-puro backbone
vector. The insert fragment of SMAD4 cDNA was sub-
cloned into the pBABE-puro backbone by using T4
ligase (NEB) subjected to Klenow enzyme reaction and
ligated. All plasmids were verified by DNA sequencing
(Genome International Biomedical Co., Ltd., New Taipei
City, Taiwan).
Retroviral production and infection of target cells
Retrovirus was generated by co-transfection of pBabe-
puro empty vector or pBabe- puro-SMAD4 with pVSV-G
(envelope) and pVSV-GP (packaging) plasmids in 293 T
cells. Target cells were infected overnight with 4 ml of
virus-containing medium in the presence of 10 μg/ml
polybrene. The following day, cells were cultured in fresh
medium and allowed to grow for another 24 hrs. After this
medium was replaced with fresh regular medium, cells
were selected with 2 μg/ml puromycin for 2 weeks. Posi-
tive stable clones were then characterized and utilized in
further assays.
Lentivirus production and shRNA for gene knockdown
All plasmids required for shRNA lentivirus production
were purchased from the National RNAi Core Facility,
Academia Sinica, Taipei, Taiwan. The pLKO.1-shRNA
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000010323 (SMAD4), and the scrambled lentiviral con-
trol vector was pLKO_TRC025. Lipofectamine 2000 re-
agent (Invitrogen, Carlsbad, CA) was used for lentiviral
production in 293 T cells with a packaging construct
(pCMV-ΔR8.91), an envelope construct (pMD.G) and
different shRNA constructs as previously described [20].
Western blotting
Western blotting was performed as described previously
[20,21]. The following antibodies were used in this study:
anti-SMAD4 (sc-7154 or sc-7966), anti-E-cadherin (sc-
8426), anti-vimentin (sc-7557), anti-CD133 (sc-8304), anti-
CD44 (sc-18849), anti-Sp1(sc-14027), anti-c-Jun (sc-1694),
anti-Fos (sc-52), anti-Fast-1 (sc-377358), anti-Hes1 (sc-
25392), anti-GAPDH (sc-32233; Santa Cruz Biotechnology,
Inc.), anti-p-Akt (#4060), anti-Akt (#4691), anti-p-p44/
42 (#9101),anti-p44/42 (#4695), anti-Pten (#9272), anti-
NF-κB (#4764S), anti- EGFR (#4267), anti-p-EGFR tyr
992 (#2235), anti-p-EGFR tyr 1068 (#3777), anti-Smad2/
3 (#5339), anti-p-Smad2/3 (#3101), anti-p-c-Jun (#2361;
Cell Signaling Technology, Inc.), anti-Nestin (N5413),
mouse anti-β-actin (Sigma- Aldrich Co.), anti-CD133/1
(AC133, Miltenyi Biotec.) and anti-TGF-β1 (ab9758,
Abcam, Plc.).
Quantitative reverse transcription polymerase Chain
reaction (RT-qPCR) analysis
Total RNA prepared from samples was used for cDNA
synthesis. PCR amplification and results of the delta
computed tomography (CT) measurements were de-
scribed previously [20,22]. The primers sequence used in
thi stsudy were as follows: GAPDH primer sequences:
forward 5′-GAAGGTGAAGGTCGGAGTCA-3′. Reverse
5′-AATGAAGGGGTCATTGAT GG-3′. SMAD4 primer
pair: Forward 5′-CGCTTTTGTTTGGGTC AACT-3′. Re-
verse: 5′-CCCAAACATCACCTTCACCT-3. CD133 pri-
mer pair: Forward 5′-CCCCAGGAAATTT GAGGAA
C-3′. Reverse 5′- TC CAACAATCCATTCCCTGT-3′. E-
cadherin primer pair: Forward 5′-ATTGCAAATTCCT
GCCATTC-3′. Reverse 5′-CTCTTCTCCGCCTCCTTC
TT-3′. N-cadherin primer pair: Forward 5′-CCTTGTGCT
GATGTTTGTGG-3′. Reverse 5′-TGGATGGGTCTTT
CATCCAT-3′. vimentin primer pair: Forward 5′-GGGA
GAAATTGC AGGAGGAG-3′. Reverse 5′-ATTCCACT
TTGCGTTCAAGG-3′. CD44 primer pair: Forward 5′-
AG ACACCATGCATGGTGCACC-3′. Reverse 5′-TAA
CAGCATCAGGAGTG-3′. EGFR primer pair: Forward
5′-TCAGCCACCCATATGTACCA-3′. Reverse: 5′-CAT
TC TTTCATCCCCCTGAA-3′. VEGF primer pair: For-
ward 5′-CCCACTGAGGAGTCC AACAT-3′. Reverse:
5′-T GCATTCACATTTGTTGTGC-3′. The PCR reac-
tions were repeated three times from three independent
experiments.Transient transfections and luciferase reporter assays
Transient transfections and SBE4 (four repeats of SMAD
binding element), CD133 and Nestin luciferase reporter
assays were performed as described previously [20].
Cell proliferation assay
Cell proliferation assay was performed as previously de-
scribed [20,22]. Briefly, 5X 103 cells were seeded in 96-
well plates, and incubated overnight. The cells were
treated with or without drugs, and incubated for 1 to
3 days. 5 mg/ml MTT (thiazolyl blue tetrazolium brom-
ide) (Americo Chemical Co) 25 μl in 500 μl medium was
then added, and incubated for another 2 hours for reac-
tion. The medium was removed, and crystal was com-
pletely dissolved with 200 μl DMSO (Sigma). The OD570
reading was then detected with a BioTek ELISA reader
(Molecular Device, Sunnyvale, CA).
In vitro cell migration/invasion assays
For wound healing cell migration assay, cells were pre-
treated with 0.02% (0.2 mg/mL) mitomycin C for 2 hours,
and wounded by removing a 300–500 μm-wide strip of
cells across the well with a standard 200 μL yellow tip.
Wounded monolayers were washed twice with 1xPBS to
remove nonadherent cells. The cells were cultured in low
FBS media and incubated for pre-determined times to
monitor wound closing. Wound closure was recorded by
phase-contrast microscopy according to previously pub-
lished protocols [20,22]. For transwell migration assays,
5 × 104 cells were plated in the top chamber with a non-
coated filter membrane (6-well insert, pore size 8 μm; BD
Biosciences, San Jose, CA) in low serum medium. The
bottom medium was supplemented with 10% FBS. Cells
were incubated for 24 hours. Cells that did not migrate
through the pores were removed by cotton swab. Cells on
the lower surface of the membrane were stained with crys-
tal violet before photography. The crystal violet was dis-
solved in 10% acetic acid and absorbance was measured
by using the BioTek enzyme-linked immunosorbent assay
(ELISA) reader OD570 (Level BioTek Instruments, Inc.,
Winooski, VT) for quantitative analysis [20].
Mice and injections
To study in vivo tumorigenicity, pathogen-free female C.
B17/lcr- SCID mice, eight weeks old, were purchased
from BioLASCO Taiwan Co., Ltd. (Taipei, Taiwan). Tech-
nology from Charles River Laboratories (Wilmington,
MA, USA) was used for breeding in the animal center at
the Department of Medical Research, Kaohsiung Medical
University (KMU) Hospital. Mice were housed at the Ex-
perimental Animal Center, KMU under specific pathogen-
free (SPF) conditions under protocols approved by the
KMU IACUC institutional guidelines for the care and use
of experimental animals were followed. Mice were injected
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in 0.1 ml of medium. After two months, tumor volumes,
overall health and total body weights of the mice were
assessed as previously described [20]. Each experimental
group contained > 4 mice.
Mouse surgery, necropsy, histopathology and
immunohistochemistry
Tissue samples were fixed in 10% buffered formalin for
12 h, washed with PBS and transferred to 70% ethanol,
embedded in paraffin, sectioned and stained with hema-
toxylin and eosin (H&E). Immunohistochemical analysis
of SMAD4, EGFR, E-cadherin, CD133 and Nestin were
performed as described previously [8,20].
Statistical analysis
Data are presented as mean ± standard error of the
mean. The continuous data were statistically analyzed
using Student’s t-test and categorical data were subjected
to Chi-square test. All statistical calculations were per-
formed using SAS for Windows version 12.2 (SAS, Inc.,
Cary, NC). A p value of less than 0.05 was considered
significant [20].
Results
Generated stable SMAD4 over-expression and knockdown
of human PDAC cells
To gain insight into the functional role of SMAD4 loss
in PDAC cells, we first selected two SMAD4-deficient
PDAC cell lines (AsPC-1 and CFPAC-1) and SMAD4
wild-type PANC-1 cells as the model cell lines in which
to study the anti-tumor effects of SMAD4 in human
PDAC. We generated the pBabe retrovirus construct
expressing human SMAD4 to restore SMAD4 gene ex-
pression in SMAD4-deficient PDAC cell lines. To verify
the restoration of SMAD4 in SMAD4-null AsPC-1 and
CFPAC-1 cells, we first performed RT-qPCR analysis to
examine the SMAD4 mRNA expression levels in those
stable SMAD4 reconstituted PDAC cells; our results
showed that the SMAD4 mRNA levels increased about
10-fold in comparison with puro control cells (data not
shown). Western blotting analysis further confirmed
the restoration of SMAD4 protein expression in the
SMAD4-deficient PDAC cell lines AsPC-1, and CFPAC-1
(Figure 1A).
Further, we determined that the intact TGF-β signal
pathway was fully restored in AsPC-1 and CFPAC-1 stable
SMAD4 reconstituted cells by using a SBE4 luciferase re-
porter assay, and by detecting the levels of SMAD2 phos-
phorylation after TGF-β1 treatment in AsPC-1 cells after
SMAD4 restoration (Figure 1B and C). We also observed
that TGF-β1 treatment leads to nuclear translocation
of SMAD4 in SMAD4-re-expressing AsPC-1 cells by
immunofluorescence analysis (Figure 1D). Meanwhile,we utilized a shRNA-mediated RNA interference ap-
proach to knockdown the expression of SMAD4 in the
PANC-1 cell line. Results of Western blots from the
PANC-1 shSMAD4 cells showed a significant reduc-
tion of SMAD4 protein levels compared to mock con-
trol cells (Figure 1A). We also confirmed the reduced
TGF-β1 signaling by phospho-SMAD2 western blot
analysis and SBE4-luciferase activity assay in PANC-1
shSMAD4 cells when compared with control cells.
(Figure 1B and C).
SMAD4 restoration does not affect their proliferation
in vitro and in vivo, but increases PDAC cells migration
in vitro
Next, we explored the overall physiological effects of
SMAD4 re-expression on PDAC cells in vitro. To deter-
mined if SMAD4 restoration has an effect on cell pro-
liferation in SMAD4-deficient PDAC cells in vitro, we
performed MTT assays in AsPC-1 and CFPAC-1 SMAD4
cells to determine the growth inhibitory effect, if any, of
SMAD4. As shown in Figure 2A, our results indicated that
SMAD4 restoration in AsPC-1 and CFPAC-1 cells did not
significantly decrease the cell proliferation rate over that
of the control cell lines following 3 days of normal cell
culture condition. Thus, we concluded that SMAD4 res-
toration in most PDAC-deficient cell lines has a minimal
effect on cell proliferation in vitro. Similarly, SMAD4
shRNA lentivirus-mediated stable knockdown for SMAD4
expression does not significantly affect cell growth in
PANC-1 cells in vitro (Figure 2A). In addition, our in vivo
study using subcutaneous xenografts in SCID mice re-
vealed that SMAD4 re-expression in AsPC-1 cells or its
knockdown in PANC-1 does not significantly affect tumor
growth in vivo (Figure 2B).
To further investigate the effect of SMAD4 expression
on the migratory potential of AsPC-1, CFPAC-1 and
PANC-1 cells in vitro, in vitro wound healing assays
were employed in SMAD4-proficient and -deficient
CFPAC-1 and AsPC-1 cells. Monolayers of cells were
pretreated with mytomycin-C for 2 hrs before being
scratched with a pipette tip, and then cultured in the
regular culture condition containing 5% fetal bovine
serum (FBS). After overnight incubation, our results in-
dicated that SMAD4 restoration significantly enhanced
the ability in vitro of CFPAC-1 and AsPC-1 cells to
migrate as compared to control cells (Figure 2C). In
addition, knockdown of SMAD4 by shRNA significantly
decreased the in vitro migratory potential of PANC-1
cells (P < 0.05; Figure 2C). Further, our results with in -
vitro invasion assay using a transwell chemotaxis inva-
sion approach in AsPC-1 and PANC-1 cells also showed
that SMAD4 enhanced the invasive ability of PDAC
cells in vitro (P < 0.05; Figure 2D and Additional file 1:
Figure S1).
Figure 1 Generated stable SMAD4 rerexpressing or knockdown of SMAD4 in human PDAC cells. (A) Western blot analysis indicated that
SMAD4 was successfully restored or knocked down in human PDAC cells as compared to control cells. β-actin was used as an internal control.
(B) AsPC-1, CFPAC-1 and PANC-1 SMAD4 proficient and deficient cells were transiently transfected with SBE4 luciferase reporter and Renilla luciferase
constructs. Cells were treated under the indicated conditions for 24 hours. Luciferase reporter assays were conducted using a dual luciferase
assay, and Renilla luciferase activity was used as an internal control. Mean + SE (n = 3) *P <0.01. (C) Western blot detection of total and phosphorylated
SMAD2 in SMAD4 proficient or deficient AsPC-1 and PANC-1 cells with or without TGF-β (10 ng/μl). Result confirmed TGF-β increased phosphorylation
of SMAD2 in the SMAD4 restoration cell lines. β-actin was used as an internal control. (D) Immuno- fluorescence analysis confirmed that SMAD4
expression in AsPC-1 SMAD4 cells and mock control cells, and the nuclear localization of SMAD4 was observed in response to TGFβ1 treatment
(magnification ×100).
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gene expression
We and others have shown that SMAD4 is involved in
regulating E-cadherin expression in PDAC [8]. One recent
study also suggested that SMAD4 is required for TGF-β-
induced EMT to mediate bone metastasis of breast cancer
cells [23]. Thus, to further confirm that SMAD4 re-
expression was involved in alterations of the EMT pheno-
type marker in PDAC, we performed RT-qPCR and
Western blot analysis to evaluate the mRNA and protein
levels of EMT-related markers in SMAD4-proficient
and -deficient PDAC cells. As shown in Figure 3A, we
observed up-regulation of smooth muscle actin and
vimentin in the mRNA as well as protein levels and sig-
nificantly lower levels of E-cadherin in SMAD4-proficientPDAC cells. Meanwhile, pancreatic CSC markers such as
CD44, Nestin and CD133 have been shown to play im-
portant roles in maintaining PDAC progression. To assess
whether SMAD4 re-expression induces alterations in the
expression of these CSC markers in PDAC, we further
determined the mRNA and protein expression levels of
CD44, CD133 and Nestin on SMAD4-deficient and
-proficient PDAC cells by RT-qPCR and Western blot
analysis. Our Western blot analysis showed that SMAD4-
proficient cells express more Nestin and CD44 proteins
than SMAD4-deficient cells (Figure 3B). In contrast, the
level of CD133 protein expression was reduced in the
SMAD4-proficient cells compared to SMAD4- deficient
cells (Figure 3B). Additional IHC analysis confirmed a sig-
nificant increase of E-cadherin, EGFR and CD133 signals
Figure 2 SMAD4 does not significantly affect PDAC cell viability or proliferation, but increase PDAC cell motility in vitro. (A) SMAD4
does not significantly affect growth of PDAC cells in vitro. Cells were seeded (5X103 cells per well) in 96-well plates and cell proliferation rates
were determined by MTT assay at indicated time points. (B) SMAD4 does not affect PDAC tumor growth in SCID mice. Xenograft tumors were
established using SMAD4 proficient or deficient AsPC-1 and PANC-1 cells implanted by s.c injection (1 × 106 cells) and analyzed after 8 weeks.
Tumor weights were measured at autopsy. Mean + SE (n = 6). (C) Wound healing assays indicated that SMAD4 restoration reduces PDAC cells
migration in vitro. The closure rates of cell free gap were recorded by phase contrast microscope after overnight incubation. Similar results were
reproduced in three independent experiments. (magnification x40). (D) SMAD4 promotes the invasive ability of PDAC cells in vitro. Invaded cells
were fixed and stained with crystal violet, and quantitative results were normalized against vector controls. Mean + SEM (n > 3). *p < 0.05.
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tumor samples belonging to PANC-1 shSMAD4 tumors
as compared with the control group (Additional file 2:
Figure S2). Meanwhile, luciferase reporter assays also con-
firmed transcriptional regulation of the CD133 and Nestin
genes by SMAD4 in PDAC cells (Figure 3C(a and b)).
Re-expression of SMAD4 reduces EGFR and VEGF
expression and repression phosphorylation in the Akt
and ERK signaling pathways, but enhances the p38 MAP
kinase pathway
SMAD4 has been shown to influence EGFR and VEGF
expression in human normal pancreatic ductal cells
(HPDEC) and Hs766T human pancreatic cancer cells
[24,25]. To confirm these finding, cell lysates were col-
lected from stably-SMAD4-expressing PDAC cells and
control groups to examine the levels of VEGF and EGFR
protein expression as well as phosphorylated EGFR by
Western blot analysis. Western blot analysis revealedsimilar results in our PDAC cells to those of the previ-
ous studies. As shown in Figures 3B & 4A, our Western
blot analysis revealed that SMAD4 re-expression results
in a decreased VEGF and EGFR protein levels. In addition,
the reduced levels of EGFR leads to decreased EGFR
phosphorylation levels at Y992 and T1068, and decreased
phosphorylation of EGFR also elicits reduction of several
downstream kinase pathways. The involvement of the ERK
(p44/42) and Akt pathways in EGFR-dependent phosphor-
ylation cascades is well recognized. Activation of the non-
SMAD Akt and MAPK pathways, particularly p38 and
p44/42 ERK, has been implicated in TGF-β1 signaling. To
further determine the potential relationship of these kinase
pathways to SMAD4 loss in PDAC cells, the levels of
p-Akt, p-p44/42 and p-p38 were examined by Western
blot analysis in SMAD4-reconstituted and vector-control
PDAC cells. Western blot analysis revealed that the phos-
phorylation levels of p44/42 and Akt were both reduced in
AsPC-1 and CFPAC-1 SMAD4-reconstituted cells, but
AB C
Figure 3 SMAD4 reduces E-cadherin, VEGF, EGFR and CD133 expression, but increases TGFβ1/Nestin and CD44 protein levels in PDAC.
(A) SMAD4 modulates mRNA levels of EMT and CSC markers in PDAC cells. RT qPCR analyses were performed in AsPC-1 and PANC-1 SMAD4
deficient or proficient cells. Compared to the control, restoration of SMAD4 reduces mRNA level of EGFR, VEGF, CD133 and E-cadherin, but
increased Vimentin, SMA, Nestin and CD44 mRNA expression in PDAC. Data were means ± SD of triplicates. *P < 0.05 (B) Western blot analysis of
three PDAC cell lines, which had overexpression or knockdown for SMAD4 revealed that the expression levels of CD133, Nestin, EGFR, VEGF and
EMT markers in indicated cell lines. β-actin was included as a loading control. (C) Luiferase activity assays for the analysis of CD133 and Nestin
transcriptional activities in PDAC cells. Reproter assays were performed using CD133-luc (a) and Nestin-luc(b) reporter constructs in AsPC-1,
CFPAC-1 and PANC-1 Smad4 proficient and deficient cells. Bars represent means derived from at least 3 independent experiments. *P < 0.01.
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pression was not increased in SMAD4 transfected cells
compared to cells with the control vectors (Figure 4A),
implying that SMAD4 loss not only increased the protein
and phosphorylation levels of EGFR, but also activated the
EGFR downstream signaling. We also observed that the
re-expression of SMAD4 increased the phosphorylated
and total levels of protein in the p38 MAP kinase pathway
by Western blot analysis (Figure 4A). To confirm these
findings, we used the shRNA strategy to compare PANC-
1 cells with control shRNA; similar results were obtained
(Figure 4A). These findings strongly suggest that re-
expression of SMAD4 attenuates the Akt and Erk (p44/
42) pathways and promotes p38 kinase activation in
PDAC. Notably, in our Western blots to detect SMAD4-
signaling-mediated effects on the expression of majortranscriptional factors, we observed that SMAD4 elevated
the expression of the transcriptional factors c-Jun, c-fos,
Fast-1, Hes-1 and NF-κB but inhibited the expression of
the transcriptional factors Sp-1 in PDAC cells (Figure 4B).
SMAD4 defect confers chemoresistance and leads to
augmented EGFR-mediated cancer cell motility in PDAC
Since somatic inactivation of SMAD4 occurs primarily
at later stages of pancreatic malignancy, and SMAD4
inactivation was reported to serve as a worse prognos-
tic factor in PDAC patients who received adjuvant
radiotherapy and chemotherapy, we next investigated
whether restoration of SMAD4 function in PDAC cells
was associated with decreased chemoresistance and
survival in vitro [26,27]. In this experiment, SMAD4-
proficient and -deficient PDAC cells were treated with
Figure 4 SMAD4 modulates multiple kinase pathways and influences transcriptional factors expression. (A) Restoration of SMAD4 results
in a marked increase of p38 MAPK activation, but significantly attenuated the phosphorylation (activation) of EGFR and its downstream signals
p44/42 (MEK) and Akt pathways in PDAC cells. (B) SMAD4 affects the expression transcriptional factors in PDAC cells. Total protein extracted from
indicated cells were lysed for Western blot analysis. Western blots were then performed with the indicated antibodies. β-actin was served as an
internal control.
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(Cis; 5 μM), gemcitabine, (Gem; 2 μM) and paclitaxol
(Pac; 1 μM). Cells were seeded into 96-well plates in
triplicate, treated with one of the chemotherapy drugs
for 3 days, then analyzed by MTTassay, a commonly-used
assay to measure cell viability after different chemotherapy
drug treatments. Cell survival rates were measured to
compare the SMAD4-positive and -negative groups in
responding to different chemotherapy agents, and our
in vitro data showed that the inactivation of SMAD4 may
contribute to an increase in chemo-sensitivity in PDAC to
different chemotherapy drugs (Figure 5 and Additional
file 3: Figure S3).
In addition, many studies indicate that the TGF-β1 and
EGFR signaling pathways are frequently activated during
pancreatic carcinogenesis, and they have been shown to
be crucial in promoting tumor cell migration and invasion
[28,29]. We therefore investigated the relationship be-
tween SMAD4 status and cell migration in PDAC induced
by the TGF-β1 and EGFR pathways. To investigate
the specific effect of these two inhibitors on PDAC cellular
migration independent of their proapoptotic effects
in vitro, we first tested the IC50 values of each compound
and applied a dose 5-fold below the IC50 value in order to
eliminate any cytotoxic effect on proliferation and observethe drug’s anti-migration function in vitro (Additional
file 4: Figure S4). We investigated whether inactivation of
TGF-β1 by SB inhibitor 431542 suppresses the motility of
SMAD4-positive or -negative PDAC cells in vitro. As
shown in Figure 6, treatment of SMAD4-re-expressing
AsPC-1 cells with 0.5 μM SB431542 caused a dramatic re-
duction in migration, but had no effect on these processes
in SMAD4-null AsPC-1 control cells. Further, to evaluate
whether inhibition of EGFR signaling can inhibit PDAC
cell migration in vitro, wound healing assays were applied
to SMAD4-positive and -negative PDAC cells after admin-
istration of 0.5 μM gefitinib, an EGFR tyrosine kinase in-
hibitor. The results showed that gefitinib treatment did
not reduce cell migration of SMAD4-positive PDAC
cells. In contrast, SMAD4-negative PDAC cells with
high levels of EGFR expression exhibited significantly
reduced cell motility when also exposed to gefitinib (P
< 0.05; Figure 6 and Additional file 5: Figure S5). The
same results were obtained by treating SB 431542 and
gefitinib in PANC-1 shSMAD4 and pLKO.1 control
cells (Figure 6). Our results imply that the efficacy of ge-
fitinib treatment of PDAC cells is likely dependent on
the cells’ EGFR activation status and, in particular, the
loss of SMAD4. Notably, wound healing assays revealed





































































































































































































































Figure 5 SMAD4 loss contributes to chemoresistance of PDAC cells. AsPC-1, CFPAC-1 and PANC-1, SMAD4 deficient and proficient cells were
treated with different concentration of cisplatin (Cis; 5 μM), paciltaxol (Pac; 1 μM) and gemcitabine, (Gem; 2 μM) for 3 days. Chemosensitivity
testing of PDAC cells using the MTT colorimetric assay. The data indicates SMAD4 increases drug sensitivity to three different chemo drugs in
PDAC cells. Data were means ± SD of triplicates. *P < 0.01.
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migration in our cell culture assays (Additional file 5:
Figure S5).
Discussion
SMAD4, also known as deleted in pancreatic carcinoma,
locus 4 (DPC4), was first identified on the basis of frequent
homozygous deletions and mutations affecting 18q21.1 in
the pancreatic tumor, and was found to be involved in the
TGF-β1 signaling pathway [11,30]. Germline mutations in
SMAD4/DPC4 have also been identified in certain types of
juvenile polyposis [31,32]. Hahn and colleagues reported
that about 90 percent of pancreatic carcinomas show allelic
loss at chromosome 18q21.1, and further studies have con-
firmed that the SMAD4/DPC4 gene, localized to 18q21,
was the target for 50% of the PDAC that exhibited 18q de-
letion [12]. During carcinogenesis, TGF-β1 may act in an
autocrine and/or paracrine fashion to exert a biphasic ef-
fect on cancer progression. Early in tumor formation,TGF-β1 functions to suppress cell cycle progression and
block tumor growth. In contrast, cancer cells later adapt to
develop a resistance to TGF-β1-mediated growth inhib-
ition by increasing expression of TGF-β1 antagonist, mu-
tating the TGF-β1 receptor or inactivating the SMAD4
gene. Subsequently, TGF-β1 ceases to function in tumor
suppression and switches to the converse role of enhancing
tumor metastasis by promoting tumor cells’ epithelial-
mesenchymal transition (EMT) or inducing the angiogenic
phenotype [33,34]. TGF-β1 is known to transduce sig-
naling cascades through SMAD-dependent, as well as
SMAD-independent, non-canonical pathways. A num-
ber of studies have reported that TGF-β1 can activate
non-canonical SMAD-independent pathways through
Ras/Erk (p44/42), PI3K/Akt, JNK or TAK1/p38 kinase
[35,36]. However, the overall effect of Erk, Akt or p38
MAPK activation by TGF-β and the biological conse-
quences are poorly characterized. Upon SMAD4 inactiva-
tion or deletion, TGF-β1 may preferentially signal through
Figure 6 SMAD4 proficient PDAC cells were more likely to respond to TGF-β1 inhibitor treatment, but SMAD4 deficient PDAC cells
were more sensitive towards EGFR inhibitor treatment to block cell migration in vitro. AsPC-1 and PANC-1 SMAD4 deficient and proficient
cells were treated with TGF-β1 inhibitor SB231542 (0.5 μM) or EGFR inhibitor gefitinib (0.5 μM) and subjected to in vitro wound-healing assay.
Each monolayer was scratched and incubated for overnight. The closure rate was photographed to compare their migratory ability between
SMAD4 deficient and proficient PDAC cells with or without TGF-β1 or EGFR inhibitors treatment. Images are representative of three independent
experiments (magnification 40×). P < 0.05.
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SMAD-dependent pathway, leading to the phenotypic
changes seen in tumor cells.
The study reported by Dai et al. [37] revealed that he
antitumor activity of SMAD4 induces G1 arrest and apop-
tosis through the nuclear translocation of SMAD4 in
MDAMB468 breast cancer cells, revealing the anti-tumorproliferation mediation of SMAD4-dependent signaling.
Although most attention has focused on the cell cycle
arrest mediated by TGF-β1/SMAD4 signaling, the other
tumor suppressive effects of SMAD4 in preventing late
stage tumor progression are still not fully understood.
Until recently, our group and others have found SMAD4
involved in suppression of metastasis, angiogenesis and
Chen et al. BMC Cancer 2014, 14:181 Page 11 of 14
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[21,38]. For example, Schwarte- Waldhoff and his col-
leagues reported that the restoration of SMAD4 in
SW480 colon cells reduced expression levels of the en-
dogenous urokinase-type plasminogen activator and
plasminogen-activator-inhibitor-1 (PAI-1) genes, involved
in the degradation of extracellular matrix proteins and the
control of tumor cell migration and invasion [39]. In 2000,
they further demonstrated that SMAD4 re-expression in
the human PDAC cell line Hs766T suppresses angiogen-
esis through down-regulation of VEGF and up-regulation
of throbospondin-1 (TSP-1), a potent endogenous angio-
genesis inhibitor [25]. Recently, our research group also
reported that SMAD4 suppresses the development of ma-
lignant phenotypes of human colorectal cancer through
interacting with HIF1α to suppress VEGF and MMP ex-
pression under hypoxic conditions [21]. Although these
studies provide promising evidence of the role of SMAD4
as a tumor suppressor gene, our mechanistic understand-
ing of SMAD4 is still in its infancy.
In the present study, using human PDAC cell lines,
we first examined the overall effects of the restoration
and knockdown SMAD4 expression in human PDAC
cells. Specifically, we found that all PDAC cells exhibit
increased cell migration in vitro after SMAD4 re-
expression, although PDAC cell growth was not signifi-
cantly affected after SMAD4 reconstitution. In addition,
we observed that SMAD4 deficiency in human PDAC
cells induces E-cadherin expression and such cells ex-
hibit epithelial morphology, a result consistent with our
previous report with SMAD4-conditional knockout mice















Figure 7 A Model of phenotypic alteration involving SMAD4 loss in P
morphology, which high express Nestin, SMA, CD44 gene, with the increas
more high expression levels for the c-Jun, c-Fos, Hes1 NF-κb transcription f
more well differentiate epithelial like (cobblestone) morphology and leads
expressions with high levels of activation p-44/42 and PI3K/Akt signaling pmodels of Pdx Kras Smad4L/L Ink/ArfL/+ mice develop
more well-differentiated lesions with glandular structures
of PDAC tumors than SMAD4 wild type Pdx Kras Ink/
ArfL/+ mice [8]. Here, we also demonstrated an increase in
the noncanonical or non-SMAD TGF-β pathways, includ-
ing the MEK/ERK and PI3K/Akt signaling pathways,
in SMAD4-negative PDAC cells compared to SMAD4-
positive PDAC cells. Intriguingly, we also observed the
down-regulated PTEN gene expression in SMAD4-
deficient PDAC cells, an effect which may be partly due to
the mediation of the inhibitory effects of NF-κB activation
[40]. Previous studies have shown that TGF-β-activated
kinase 1 (TAK1) is implicated in p38 MAPK activation
in response to TGF-β1 in several cell systems [41]. In
addition, TGF-β-induced EMT was blocked by inhibit-
ing the activation of p38 MAPK in mouse mammary
epithelial cells, and p38 MAPK inhibitors blocked TGF-
β1-stimulated migration of non-tumor and tumor cells,
which suggest that p38 MAPK may act in parallel or in
cooperation with a SMAD-dependent pathway in chemo-
tactic responses to TGF-β1 [42,43]. In this study, we also
observed an increased activation of the p38 MAPK path-
way in the presence of SMAD4 in PDAC. In addition, our
result revealed that restoration of SMAD4 induces the in-
creased activation of p38 MAPK signaling, which may in
turn enhance the expression of c-Jun, c-fos or Fast-1 tran-
scriptional factors in PDAC [44,45].
Most importantly, our present study provides the first ex-
perimental evidence that inactivation of SMAD4 enhances
EGFR and CD133 expression, whereas re-expression of
SMAD4 suppresses EGFR and CD133 levels in PDAC cells.
These results are consistent with a previous report usingEGFR/VEGF/CD133 (MAPK/Akt pathways)-induced cell 
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pression was found to increase EGFR expression [24].
Meanwhile, the down-regulation of EGFR expression in
SMAD4-proficient cells may result from the reduced
expression of the transcriptional factor Sp-1 (Figure 7).
Recently, the CD133 molecule has been linked to tumor
malignancy and invasiveness, and overexpression of
EGFR and its ligands significantly contributes to the ma-
lignant phenotype and correlates with decreased survival
in pancreatic cancer patients [46-49]. Further insight is
needed to evaluate the relationship between the expres-
sion levels of EGFR and the presence of CD133 in PDAC,
and the association between EGFR and CD133 may repre-
sent an important mechanism in the control of SMAD4-
inactivated PDAC cell proliferation and malignancy. Our
data further indicated increased Nestin expression upon
SMAD4 reconstitution in PDAC, a result which may be
related to the restoration of the TGF-β1/SMAD signaling
pathway in PDAC cells. Nestin was first identified as an
important neuronal stem cell marker during central ner-
vous system development [50,51]. The long carboxy-
terminal portion of Nestin has been reported to serve as
the link or cross-bridge between intermediate filaments
and microtubule, helping to mediate cell migration. Re-
cently, Matsuda and colleagues illustrated the importance
of Nestin in pancreatic cancer cell migration, invasion and
metastasis by selectively modulating the expression of
actin and other cell adhesion molecules [52]. They pro-
posed that Nestin expression is crucial for colonizing
distant sites in metastasis and thus may be a marker of
metastasis-initiated “cancer stem cells”. How SMAD4
regulates Nestin expression in PDAC is not yet clear.
The Nestin promoter does harbor several potential
SMAD-binding sites, two SBE-related sequence 5′-
CAGACA-3′-box at position -2067 and -566. Thus, it
could exert control via transcriptional regulation. More
recently, we proposed that increased Nestin expression
could provide a positive feedback loop to induce TGF-
β1/SMAD signaling by increasing the expression of
TGF-β1 and TβR1a and TβR2 receptors [20]. Nestin is
also involved in regulating the Wnt effector; the CD44
gene, a known putative cancer stem cell marker involved
in mediating tumor cell metastasis [53]. Thus, this study
provides the first evidence linking SMAD4 status and the
expression patterns of CSC markers of PDAC.
We also demonstrated that reconstitution of SMAD4
in PDAC cells resulted in an increase in apoptotic death
after treatment with cisplatin, gemcitabine, or paclitaxel
when compared with SMAD4-deficient PDAC cells. This
result is in agreement with our previously published
work in the colorectal cancer model, which found that
SMAD4 loss increased resistance to the chemotherapeu-
tic agent 5′-fluorouracil [21]. Many more recent studies
have shown that TGFβ1 and EGFR inhibitors arepromising for the treatment of pancreatic cancer
[54-56]. Like many chemotherapeutic agents, the effect-
iveness of EGFR inhibitors have been approved by Food
and Drug Administration for use in several tumor cases,
alone and in combination with gemcitabine for pancre-
atic cancer [57,58]. In the present study, we concluded
that treatment of SMAD4-proficient PDAC cells with
TGF-β1 inhibitor resulted in a profound reduction in
cell migration in vitro. In contrast, treatment with EGFR
inhibitor remarkably inhibited cell migration in SMAD4-
deficient PDAC cells, implying that the SMAD4 defect
results in a gain to the EGFR signaling pathway during
PDAC development.
Conclusions
The present study revealed the molecular basis for
SMAD4-dependent and -independent differences in
PDAC tumor biology with the aim of identifying the
subset of patients likely to respond to therapies target-
ing the TGF-β or EGFR signaling pathways (Figure 7)
The use of model system illustrated here may help to
identify additional nodes of therapeutic intervention in
PDAC patients devoid of SMAD4.
Additional files
Additional file 1: Figure S1. SMAD4 enhances migration and
invasiveness of AsPC-1 and PANC-1 cells in vitro. Representative images
of the invaded cells are represented. Invading cells on the lower surface
that passed through the filter were fixed and stained using crystal violet
in gluteraldehyde and photographed. Scale bar, 50 μm.
Additional file 2: Figure S2. Immunohistochemistry (IHC) analysis
evaluates E-cadherin, EGFR, CD133, Nestin and SMAD4 expression levels
in PANC-1 shSMAD4 and control xenograft tumors. Tumor sections were
analyzed by H&E and IHC using anti-SMAD4, anti-Ecadherin, anti-CD133,
anti-Nestin and anti-EGFR antibodies as described in Material and
methods section. Tissues were stained with 3,3′- diaminobenzidine
(brown) and counterstained with hematoxylin (blue). Scale bar, 50 μm.
Additional file 3: Figure S3. Morphological characterization under
phase contrast microscopy of cell death in SMAD4 proficient and
deficient AsPC-1 and PANC-1 cells after different chemo drugs treatment.
Bright field microscopy images are representative fields of the cell
morphology of SMAD4 proficient or deficient cells were incubated in
medium in the presence of DMSO, cisplatin (Cis), paclitaxel (Pac) or
gemcitabine (Gem) treatment for 2 days. Scale bar, 50 μm.
Additional file 4: Figure S4. Dose response of SMAD4 positive and
negative PDAC cells to SB431542 and gefitinib. The cells were treated
with various doses of SB431542 or gefitinib for 24 hours, and the cell
viability was measured by a MTT assay. Data represent the mean values
± standard error of three independent experiments.
Additional file 5: Figure S5. Quantitation of cell migratory ability in
SMAD4 proficient and deficient AsPC-1 and PANC-1 cells after different
inhibitor treatments. Wounded area per field was individually assessed
and averaged per well. To determine scale, a picture was taken of a
micrometer, and two to three fields on each filter were scored for cell
migration under an inverted microscope. Calibration was performed with
the analysis tool in Image J. Data represent relative cell migration ability
normalized to vector control cells treated with DMSO (mean ± SD, n = 3;
combined data from two independent experiments each performed in
triplicate). Significantly different (*P < 0.05) compared with different
conditions.
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